Carbidopa
Back to searchMolecule Structure
Scientific Name
Carbidopa
Description of the Drug
Carbidopa is a dopa decarboxylase inhibitor used in combination with levodopa for the symptomatic treatment of idiopathic Parkinson disease and other conditions associated with parkinsonian symptoms.
Source: DrugBank Online – DrugBank.com. Retrieved 2023-03-10 from
http://www.drugbank.ca/drugs/DB00190
http://www.drugbank.ca/drugs/DB00190
Brand Name(s)
Lodosyn
Company Owner(s)
Organon Llc, Watson Laboratories Inc, Kv Pharmaceutical Co, Abbvie Inc, Mylan Pharmaceuticals Inc, Scs Pharmaceuticals, Zydus Pharmaceuticals Usa Inc, Impax Laboratories Inc, Rising Pharma Holdings Inc, Alvogen Inc
Mechanism(s) Of Action
| Target Name | Target Type | Action Type | Target ChEMBL ID |
|---|---|---|---|
| DOPA decarboxylase | SINGLE PROTEIN | INHIBITOR | CHEMBL1843 |
Clinical Trial(s)
Unichem Links
| SureChEMBL | SCHEMBL35084 | ||||
| PharmGKB | PA448794 | ||||
| Human Metabolome Database | HMDB0014336 | ||||
| DrugBank | DB00190 | ||||
| PubChem: Thomson Pharma | 14773700 | ||||
| PubChem | 34359 | 28082766 | |||
| Mcule | MCULE-3726796258 | ||||
| LINCS | LSM-5850 | ||||
| Nikkaji | J17.160C | ||||
| PDBe | 142 | ||||
| BindingDB | 50418773 | ||||
| EPA CompTox Dashboard | DTXSID4022735 | ||||
| DrugCentral | 496 | ||||
| Brenda | 5137 | 96671 | 204537 | 86933 | 96134 |
| ChemicalBook | CB5738078 | ||||
| Guide to Pharmacology | 5159 | ||||
| rxnorm | LODOSYN | CARBIDOPA ANHYDROUS | CARBIDOPA | ||
| ChEBI | 39585 | ||||
| ZINC | ZINC000019168887 |
